TGF-β concentrations and activity are down-regulated in the aqueous humor of patients with neovascular age-related macular degeneration
| Autor: | Elisabetta Nuti, Gian Marco Tosi, Annalisa Santucci, Marcella Barbarino, Davide Marigliani, Barbara Parolini, Tommaso Bacci, Lucia Mundo, Giovanni Neri, Stefano Baiocchi, Antonio Tarantello, Elena Caldi, Fiorella Fusco, Federico Galvagni, Claudio Traversi, Chiara M. Eandi, Maurizio Orlandini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A 0301 basic medicine lcsh:Medicine Angiogenesis Inhibitors Neovascularization Macular Degeneration TGF-beta lcsh:Science Multidisciplinary Neovascularization Pathologic nAMD TGF-beta Age-related macular degeneration biology Publisher Correction Vascular endothelial growth factor A Intravitreal Injections Female Antibody medicine.symptom medicine.drug medicine.medical_specialty Down-Regulation Article Aqueous Humor Transforming Growth Factor beta1 Transforming Growth Factor beta2 03 medical and health sciences Transforming Growth Factor beta3 Ranibizumab Internal medicine TGF beta signaling pathway medicine Humans Aged Pathologic business.industry Age-related macular degeneration lcsh:R Case-control study Case-Control Studies Gene Expression Regulation Macular degeneration medicine.disease 030104 developmental biology Endocrinology nAMD biology.protein lcsh:Q business Transforming growth factor |
| Zdroj: | Scientific Reports Scientific Reports, Vol 8, Iss 1, Pp 1-9 (2018) |
| ISSN: | 2045-2322 |
| Popis: | Controversy still exists regarding the role of the TGF-β in neovascular age-related macular degeneration (nAMD), a major cause of severe visual loss in the elderly in developed countries. Here, we measured the concentrations of active TGF-β1, TGF-β2, and TGF-β3 by ELISA in the aqueous humor of 20 patients affected by nAMD, who received 3 consecutive monthly intravitreal injections of anti-VEGF-A antibody. Samples were collected at baseline (before the first injection), month 1 (before the second injection), and month 2 (before the third injection). The same samples were used in a luciferase-based reporter assay to test the TGF-β pathway activation. Active TGF-β1 concentrations in the aqueous humor were below the minimum detectable dose. Active TGF-β2 concentrations were significantly lower at baseline and at month 1, compared to controls. No significant differences in active TGF-β3 concentration were found among the sample groups. Moreover, TGF-β pathway activation was significantly lower at baseline compared to controls. Our data corroborate an anti-angiogenic role for TGF-β2 in nAMD. This should be considered from the perspective of a therapy using TGF-β inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|